Genesis Drug Discovery & Development Acquires JSS Medical Research

Genesis Drug Discovery and Development (GD3), a Contract Research Organization arm and member of Genesis Global Group (GGG), has recently completed the acquisition of JSS Medical Research to expand its clinical services portfolio.

With corporate headquarters in Montréal, Canada, and regional offices in Bogotá, Columbia, Faridabad, India, and Warsaw, Poland, JSS Medical Research provides pre- and post-approval clinical development services to support pharmaceutical, biotechnology, nutraceutical and medical device companies worldwide.

This clinical service portfolio addition will enable the GD3 member companies to expand their full-service drug research and discovery services. The merger of these two companies creates an organization that will deliver state-of-the-art scientific support and services to their combined and growing list of pharmaceutical, biotechnology and medical device clients. As one entity, they will be able to conveniently support their clients throughout the drug development life cycle. JSS Medical Research’s skilled team of world-class scientists will work synergistically and augment GD3’s existing platform of services in clinical trial support.

Genesis Global Group is a consortium of vertically integrated companies with a mission of improving patient care by cross-linking their expertise, dedication, and vision in drug discovery. Genesis Drug Discovery & Development is a fully integrated CRO providing services to support drug discovery programs of its clients.

BCF is proud to have acted on behalf of Genesis Drug Discovery & Development in this transaction with a team composed of Annie Gauthier, Jean-Christophe Imbeau, Thomas Champagne and Gabriel Melançon (Mergers & Acquisitions), Marc-André Godard and Mathieu Gendron (Taxation), Eleonora Eusepi and Ashley Weiss (Financing), Nancy Boyle and Nicolas Choueri (Employment & Labour) and Emilia Stoute (Corporate).

To read the press release, click here.